ArticleInternational urology and nephrology2026
Associations of roxadustat with copper elevation and hypothyroidism in patients on hemodialysis.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Associations of roxadustat with copper elevation and hypothyroidism in patients on hemodialysis: a critical appraisal.International urology and nephrology · 2026Article
- Copper elevation and thyroid dysfunction with roxadustat therapy: an overlooked safety concern in hemodialysis.International urology and nephrology · 2026Article
- Beyond biochemical associations: methodological gaps in a study of roxadustat, copper, and thyroid function.International urology and nephrology · 2026Article
- Comment on association of roxadustat with copper elevation and hypothyroidism in patients on hemodialysis.International urology and nephrology · 2026Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to assess the associations of roxadustat with changes in serum trace element levels and with hypothyroidism in hemodialysis (HD) patients.
methodsA total of 34 patients on HD who received weekly doses of darbepoetin-α or a continuous erythropoietin receptor activator once every 2 or 4 weeks were switched to roxadustat (70 mg, three times weekly). Levels of biomarkers for erythropoiesis and iron metabolism, trace elements (copper, zinc, and selenium), ceruloplasmin, and thyroid-stimulating hormone (TSH), free-triiodothyronine (T3), and free-tetraiodothyronine (T4) were measured in blood samples collected before the HD session on days 0 (switch to roxadustat treatment), 28, and 56.
resultsSerum copper and ceruloplasmin levels were significantly increased by roxadustat treatment on days 28 and 56, and serum selenium levels were lower on day 28. However, serum zinc levels were not changed over the 56 days. Serum TSH levels were decreased on day 28, and they then increased to baseline on day 56. Serum free-T3 and free-T4 levels were significantly decreased from day 28 to day 56. Changes in roxadustat doses were associated with changes in serum TSH, free-T3, and free-T4 levels, whereas they were not associated with serum levels of trace elements.
conclusionsRoxadustat may decrease serum TSH, free-T3, and free-T4 levels and increase serum copper and ceruloplasmin levels in HD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.